Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 255

Results For "SEC"

3011 News Found

Foreign Direct Investment in pharma grows at rapid pace: Eco Survey
News | January 31, 2022

Foreign Direct Investment in pharma grows at rapid pace: Eco Survey

In the April-September 2021 period, the FDI inflows continued to be buoyant at Rs 4,413 crore, growing at the rate of 53 per cent over the same period in 2020-21


Union Budget 2022-23 : Industry expects increased allocation to healthcare, skill development, R&D and universal health insurance
Hospitals | January 30, 2022

Union Budget 2022-23 : Industry expects increased allocation to healthcare, skill development, R&D and universal health insurance

Allocation for the healthcare sector has gone up but is still woefully short of expectations. A few leading voices from the hospital and consulting sectors share their perspective on what they expect from Budget 2022


Union Budget 2022-23 : Medtech expects incentives, GST exemptions and custom duty rationalisation
Medical Device | January 30, 2022

Union Budget 2022-23 : Medtech expects incentives, GST exemptions and custom duty rationalisation

Medtech plays a vital role in the healthcare system and players in this field believe that the budget should address some of their concerns if India has to become a formidable player


DCGI approves Bharat Biotech’s Phase 3 trials for intranasal vaccine
News | January 29, 2022

DCGI approves Bharat Biotech’s Phase 3 trials for intranasal vaccine

Intranasal vaccines are easier to administer in mass immunisation campaigns and help reduce or stop transmission


Union minister Mansukh Mandaviya launches NIPER website
Public Health | January 29, 2022

Union minister Mansukh Mandaviya launches NIPER website

The aim is to strengthen industry-academia cooperation


ARVs bottom out while CRAMS growth continues for Laurus Labs: ICICI Direct
News | January 29, 2022

ARVs bottom out while CRAMS growth continues for Laurus Labs: ICICI Direct

The management guided for ARV API & formulation demand to be normalised from Q4FY22 and reiterated the aspiration of US $ 1 billion in sales by FY23: ICICI Direct


Lonza partners with biotech firm HaemaLogiX on multiple myeloma drug candidate
Biotech | January 29, 2022

Lonza partners with biotech firm HaemaLogiX on multiple myeloma drug candidate

Company to manufacture drug substance for clinical supply of HaemaLogiX’s lead multiple myeloma drug candidate, KappaMab, at its new state-of-the-art facility in Guangzhou, China


European Commission approves Merck’s KEYTRUDA as adjuvant therapy for RCC
Drug Approval | January 28, 2022

European Commission approves Merck’s KEYTRUDA as adjuvant therapy for RCC

KEYTRUDA is now approved as monotherapy for adults with Renal Cell Carcinoma (RCC)


Biogen sells equity stake in its biosimilar JV with Samsung Biologics for US $ 2.3 billion
News | January 28, 2022

Biogen sells equity stake in its biosimilar JV with Samsung Biologics for US $ 2.3 billion

The companies will continue with their exclusive agreements, including commercialization of their current portfolio


Covaxin and Covishield granted conditional market approval
News | January 27, 2022

Covaxin and Covishield granted conditional market approval

The vaccines are currently only authorised for emergency use in the country